+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Completed

Phase 1
Age: 18Years - 60Years
All Genders
Healthy Volunteers
ID00001056

A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein gp160 of Human Immunodeficiency Virus Evaluation of a 200-mcg Dose

Led by National Institute of Allergy and Infectious Diseases (NIAID) · Updated on 2021-11-04

25

Participants Needed

3

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

To determine the safety of and immune response to vaccinia-derived HIV-1 recombinant envelope glycoprotein (gp160) at a dose of 200 mcg in human volunteers; to evaluate duration of antibody response and its relationship to the dose and frequency of inoculation. Although recent advances have been made in antiviral therapy against AIDS, there is currently no cure for AIDS. It is likely that the ultimate control of the disease depends on the development of safe and effective vaccines against HIV.

CONDITIONS

Brief Title

A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of a 200-mcg Dose

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here